| Indicators | Browse All

Valneva SE (VALN)

Healthcare | Biotechnology | Saint-Herblain, France | NasdaqGS
6.43 USD -0.15 (-2.280%) ⇩ (Aug. 28, 2026, 4 p.m. EDT)
After hours: 6.43

Short-term:★★⯪☆☆Long-term:★☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | Aug. 22, 2026, 3:44 a.m. EDT

The immediate outlook is clouded by severe fundamental deterioration and a toxic balance sheet. The company is burning cash aggressively, with free cash flow and operating cash flow both deeply negative, while gross and operating margins are in the red, indicating a broken cost structure or pricing power issues. This financial distress is compounded by a massive debt load relative to equity, creating a precarious capital structure that limits flexibility. Although the stock recently rallied off a multi-year low, the catalyst appears to be a temporary relief rally following mixed clinical data rather than a resolution of the core business problems. Analyst sentiment remains fractured, with major downgrades citing vaccine uncertainty, suggesting the market views the current price as insufficiently safe given the execution risks. With no dividend to provide income and a history of significant capital destruction over the last four years, there is no margin of safety here.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoETS ✓0.085300
AutoTheta0.086573
MSTL0.086580
AutoARIMA0.103018

Forecast horizon: 45 days | Selected: AutoETS

Forecast Reliability
Score 25%
H-stat 127.83
Ljung-Box p 0.000
Jarque-Bera p 0.009
Excess Kurtosis -0.38
Attribute Value
Sector Healthcare
Debt to Equity Ratio 259.157
Revenue per Share 1.602
Market Cap 609,714,816
Forward P/E 5.40
Beta 1.35
Profit Margins -110.29%
Website https://valneva.com

Info Dump

Attribute Value
52 Week Change -0.2394203
Address1 6 rue Alain Bombard
All Time High 67.84
All Time Low 3.62
Ask 6.73
Ask Size 1
Average Daily Volume10 Day 333,750
Average Daily Volume3 Month 76,487
Average Volume 76,487
Average Volume10Days 333,750
Beta 1.347
Bid 6.58
Bid Size 1
Book Value 0.99761665
City Saint-Herblain
Compensation As Of Epoch Date 1,767,139,200
Country France
Crypto Tradeable 0
Currency USD
Current Price 6.43
Current Ratio 2.157
Custom Price Alert Confidence HIGH
Date Short Interest 1,786,665,600
Day High 6.58
Day Low 6.43
Debt To Equity 259.157
Earnings Call Timestamp End 1,786,651,200
Earnings Call Timestamp Start 1,786,651,200
Earnings Timestamp 1,786,624,200
Earnings Timestamp End 1,786,624,200
Earnings Timestamp Start 1,786,624,200
Ebitda -98,721,000
Ebitda Margins -0.69066
Enterprise To Ebitda -7.075
Enterprise To Revenue 4.886
Enterprise Value 698,419,840
Eps Current Year -1.13
Eps Forward 1.19
Eps Trailing Twelve Months -2.07
Esg Populated 0
Exchange NMS
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fax 33 2 28 07 37 11
Fifty Day Average 5.51132
Fifty Day Average Change 0.9186797
Fifty Day Average Change Percent 0.16668959
Fifty Two Week Change Percent -23.94203
Fifty Two Week High 12.23
Fifty Two Week High Change -5.7999997
Fifty Two Week High Change Percent -0.47424367
Fifty Two Week Low 4.75
Fifty Two Week Low Change 1.6799998
Fifty Two Week Low Change Percent 0.3536842
Fifty Two Week Range 4.75 - 12.23
Financial Currency EUR
First Trade Date Milliseconds 1,620,221,400,000
Float Shares 78,631,404
Forward Eps 1.19
Forward P E 5.403361
Free Cashflow -42,501,124
Full Exchange Name NasdaqGS
Full Time Employees 620
Fullday Change -0.15
Fullday Change Percent -2.27964
Fullday Price 6.43
Gmt Off Set Milliseconds -14,400,000
Gross Margins -0.41733003
Gross Profits -59,653,000
Has Pre Post Market Data 1
Held Percent Insiders 0.0
Held Percent Institutions 0.03993
Implied Shares Outstanding 94,823,458
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Ipo Expected Date 2,021-05-06
Is Earnings Date Estimate 0
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; PF-07307405, a vaccine candidate to prevent Lyme disease cases in individuals aged five years and older and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of Europe, and internationally. Valneva SE was founded in 1998 and is based in Saint-Herblain, France.
Long Name Valneva SE
Market us_market
Market Cap 609,714,816
Market State CLOSED
Max Age 86,400
Message Board Id finmb_4550716
Most Recent Quarter 1,782,777,600
Net Income To Common -157,650,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 622,177,234
Number Of Analyst Opinions 4
Open 6.55
Operating Cashflow -55,694,000
Operating Margins -0.74915004
Payout Ratio 0.0
Phone 33 2 28 07 37 10
Post Market Change 0.0
Post Market Change Percent 0.0
Post Market Price 6.43
Post Market Time 1,787,947,805
Previous Close 6.58
Price Eps Current Year -5.690265
Price Hint 2
Price To Book 6.4453616
Price To Sales Trailing12 Months 4.265589
Profit Margins -1.10293
Quick Ratio 1.334
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.15
Regular Market Change Percent -2.27964
Regular Market Day High 6.58
Regular Market Day Low 6.43
Regular Market Day Range 6.43 - 6.58
Regular Market Open 6.55
Regular Market Previous Close 6.58
Regular Market Price 6.43
Regular Market Time 1,787,947,200
Regular Market Volume 22,286
Return On Assets -0.16683
Return On Equity -1.17846
Revenue Growth -0.277
Revenue Per Share 1.602
Sand P52 Week Change 0.20504117
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 94,823,458
Shares Percent Shares Out 0.0017
Shares Short 160,474
Shares Short Previous Month Date 1,784,073,600
Shares Short Prior Month 165,539
Short Name Valneva SE
Short Percent Of Float 0.0017
Short Ratio 1.06
Source Interval 15
Symbol VALN
Target High Price 18.0
Target Low Price 5.0
Target Mean Price 12.25
Target Median Price 13.0
Total Cash 121,526,000
Total Cash Per Share 1.282
Total Debt 210,231,008
Total Revenue 142,938,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -2.07
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 7.451795
Two Hundred Day Average Change -1.0217953
Two Hundred Day Average Change Percent -0.1371207
Type Disp Equity
Volume 22,286
Website https://valneva.com
Zip 44,800